209 related articles for article (PubMed ID: 11089243)
1. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss JL; Nitiss KC
Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
[No Abstract] [Full Text] [Related]
2. Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.
Woo MH; Vance JR; Bjornsti MA
Methods Mol Biol; 2001; 95():303-13. PubMed ID: 11089242
[No Abstract] [Full Text] [Related]
3. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
4. Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I.
Edwards TK; Saleem A; Shaman JA; Dennis T; Gerigk C; Oliveros E; Gartenberg MR; Rubin EH
J Biol Chem; 2000 Nov; 275(46):36181-8. PubMed ID: 10967121
[TBL] [Abstract][Full Text] [Related]
5. Using yeast to understand drugs that target topoisomerases.
Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
[No Abstract] [Full Text] [Related]
6. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
7. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
8. Yeast as a genetic model system for studying topoisomerase inhibitors.
Nitiss JL
Adv Pharmacol; 1994; 29B():201-26. PubMed ID: 8996609
[No Abstract] [Full Text] [Related]
9. Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs.
Reid RJ; Benedetti P; Bjornsti MA
Biochim Biophys Acta; 1998 Oct; 1400(1-3):289-300. PubMed ID: 9748633
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase enzymes as drug targets.
Guichard SM; Danks MK
Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
[TBL] [Abstract][Full Text] [Related]
12. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
13. Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae.
Zhu J; Schiestl RH
Mol Genet Genomics; 2004 Apr; 271(3):347-58. PubMed ID: 15007730
[TBL] [Abstract][Full Text] [Related]
14. Identification of the yeast TOP3 gene product as a single strand-specific DNA topoisomerase.
Kim RA; Wang JC
J Biol Chem; 1992 Aug; 267(24):17178-85. PubMed ID: 1324925
[TBL] [Abstract][Full Text] [Related]
15. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
Beck WT
J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
[No Abstract] [Full Text] [Related]
16. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
Levac P; Moss T
Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
18. Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II.
Christman MF; Dietrich FS; Fink GR
Cell; 1988 Nov; 55(3):413-25. PubMed ID: 2902925
[TBL] [Abstract][Full Text] [Related]
19. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
